Application of pharmacogenetics and pharmacogenomics in drug development and regulatory review

Genomics: Fundamentals and Applications

Volumn , Issue , 2008, Pages 357-378

  Huang, Shiew Mei ^a   Kim, Myong Jin ^a   Goodsaid, Federico ^a   Frueh, Felix ^a   Lesko, Lawrence J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350487410     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (62)

1. ICH E5. Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data, 1998. http://www.fda.gov/cder/guidance/index.htm. E5 Questions and Answers, 2004. http://www.fda.gov/cder/guidance/6200fnl.pdf.
2. Cross J, Lee H, Westelinck A, et al. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf 2002; 11: 439-446.
3. Temple RJ. Defining dose decrea. [Comment on Cross J, Lee H, Westelinck A, et al., Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf 2002; 11: 439-446]. Pharmacoepidemiol Drug Saf 2003; 12: 151-152.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients:a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
5. Huang S-M, Miller M, Toigo T, et al. Evaluation of Drugs in Women: Regulatory Perspective. In Volume 2; Section 9 -Drug Metabolism/Clinical Pharmacology (Section Editor: Schwartz J). In:Legato M, ed., Principles of Gender-Specific Medicine. San Diego, CA: Academic Press, 2004: 848-859.
6. Giacomini KM, Krauss RM, Roden DM, et al. When good drugs go bad. Nature 2007; 446: 975-977.
7. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-2279.
8. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-850.
9. Evans WE, McLeod HL. Pharmacogenomics -drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
10. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-537.
11. Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004; 21: 904-913.
12. Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005; 78: 559-581.
13. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429: 464-468.
14. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004; 3: 739-748.
15. FDA Atomoxetine Clinical Pharmacology Review, 2002. http://www.fda.gov/cder/foi/nda/2002/21-411_Strattera_biopharmr_P1.pdf.
16. FDA CDER/CBER Guidance for Industry: Exposure-Response Relationships -Study Design, Data Analysis, and Regulatory Applications, May 2003a. http://www.fda.gov/cder/guidance/5341fnl.pdf.
17. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics:gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73.
18. McLeod HL, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 567-572.
19. Thorn CF, Carrillo MW, Ramirez J, et al. Irinotecan pathway, March 10, 2005. http://www.pharmgkb.org/search/pathway/irinotecan/liver.jsp.
20. Ratain M. “Special consideration of individual metabolic biomarkers: UGT1A1” presentation at the FDA/PhRMA/JHU educational workshop, Rockville, MD, Sep 13-14, 2004. http://www.fda.gov/cder/offices/ocpb/workshops.htm.
21. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-1419.
22. Budnitz DS, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147: 755-765.
23. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351: 2827-2831.
24. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704.
25. Huang S-M. “Regulatory issues in genotyping metabolizing enzymes -CDER Perspective” presentation at the FDA/PhRMA/JHU educational workshop, Rockville, MD, Sep 13-14, 2004. http://www.fda.gov/cder/offices/ocpb/workshops.htm.
26. Andersson T. “Special consideration of individual metabolic biomarkers: CYP2C19” presentation at the FDA/PhRMA/JHU educational workshop, Rockville, MD, Sep 13-14, 2004. http://www.fda.gov/cder/offices/ocpb/workshops.htm.
27. Flockhart D. “Special consideration of individual metabolic biomarkers: CYP2D6” presentation at the FDA/PhRMA/JHU educational workshop, Rockville, MD, Sep 13-14, 2004. http://www.fda.gov/cder/offices/ocpb/workshops.htm.
28. Milos P. “Special consideration of individual metabolic biomarkers: CYP2C9” presentation at the FDA/PhRMA/JHU educational workshop, Rockville, MD, Sep 13-14, 2004. http://www.fda.gov/cder/offices/ocpb/workshops.htm.
29. Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002; 72: 76-89.
30. Liou YJ, Wang YC, Bai YM, et al. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiol 2004; 49: 167-173.
31. Wan YJ, Poland RE, Han G, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenet 2001; 11: 489-499.
32. Furman KD, Grimm DR, Mueller T, et al. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenet 2004; 14: 279-284.
33. Blaisdell J, Mohrenweiser H, Jackson J, et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenet 2002; 12: 703-711.
34. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-515.
35. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
36. Huang S-M, Temple R, Throckmorton DC, et al. Drug-drug interactions: study design, data analysis, and implications for dosing recommendations. Clin Pharmacol Ther 2007; 81: 298-304.
37. Huang S-M, Lesko LJ. Application of pharmacogenomics in clinical pharmacology. Part I, Molecular Medicine: Correlation Between Genes, Diseases and Biopharmaceuticals. In: Knablein J, Muller RH, eds. Modern Biopharmaceuticals -Design, Development and Optimization. Hoboken, NJ: Wiley-VCH, 2005: 49-70.
38. Salerno RA, Lesko LJ. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics. 2004a; 5: 503-505.
39. Salerno RA, Lesko LJ. Pharmacogenomics in drug development and regulatory decision-making:the Genomic Data Submission (GDS) proposal. Pharmacogenomics. 2004b; 5: 25-30.
40. Leighton JK, DeGeorge J, Jacobson-Kram D, et al. Pharmacogenomic data submissions to the FDA: non-clinical case studies. Pharmacogenomics 2004; 5: 507-511.
41. Ruaño G, Collins JM, Dorner AJ, et al. Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies. Pharmacogenomics. 2004; 5: 513-517.
42. Trepicchio WL, Williams GA, Essayan D, et al. Pharmacogenomic data submissions to the FDA:clinical case studies. Pharmacogenomics 2004; 5: 519-524.
43. FDA CDER/CBER/CDRH Guidance for Industry: Pharmacogenomic Data Submission, Companion Guidance, posted on August, 2007. http://www.fda.gov/cder/guidance/7735dft.pdf.
44. Goodsaid F, Frueh FW. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006; 7: 773-782.
45. Goodsaid F, Frueh FW. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 2007; 9: E105-E108.
46. FDA/DIA workshop: co-development of drug, biological, and device products, July 29, 2004, Arlington, VA. Washington, DC: US Food and Drug Administration/Horsham, PA: Drug Information Association.
47. FDA drug-diagnostic co-development concept paper, April 2005. http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf.
48. FR notice 2000: labeling guideline (Federal Register 65: 247; 81082-81131; December 22, 2000).
49. FDA mission statement; 2004. http://www.fda.gov/opacom/morechoices/mission.html.
50. FDA strategic plan: FDA Commissioner, McClellan, MB, FDA strategic action plan; August 2003b. http://www.fda.gov/oc/mcclellan/strategic.html.
51. FDA whitepaper: innovation or stagnation, challenge, and opportunity on the critical path to new medical products; 2004. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
52. FDA CDER/CBER/CDRH guidance for industry: pharmacogenomic data submission, posted on March 22, 2005. http://www.fda.gov/cder/guidance/6400fnl.pdf.
53. Frueh FW, Huang S-M, Lesko LJ. Editorial: regulatory acceptance of toxicogenomics data. Environ Health Perspect 2004; 112: A663-A664.
54. Frueh FW, Goodsaid F, Rudman A, et al. The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J 2005; 5: 218-220.
55. Goodsaid F, Huang S-M, Frueh F, et al. Regulatory guidance and application of genomic biomarkers in drug development. In: Steven H, Wong Y, Linder M, Valdes R, eds. Pharmacogenomics and Proteomics. Washington DC: AACC Press, 2006: 41-52.
56. Huang S-M, Goodsaid F, Rahman A, et al. Application of pharmacogenomics and clinical pharmacology. Toxicol Mech Meth 2006; 16: 89-99.
57. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 2004; 3: 763-769.
58. Buckman S, Huang S-M, Murphy S. Medical product development and regulatory science for the 21st century: the critical path vision and its impact on health care. Clin Pharmacol Ther 2007; 81: 141-144.
59. Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 2007; 81: 807-816.
60. Woodcock J. The prospects for “personalized medicine” in drug development and drug therapy. Clin Pharmacol Ther 2007; 81: 164-169.
61. Amur S, Frueh F, Lesko LJ et al. Integration and Use of Biomarkers in Drug Development, Regulation and Clinical Practice-A U.S. Regulatory perspective Biomarkers in Clinical Pharmacology Review, Biomarkers in Medicine 2008; 2(3): 305-311. (doi:10.2217/17520363.2.3.305).
62. Huang S-M, Temple R. Is this the drug or dose for you?-Impact of ethnic factors in global drug development, regulatory review and clinical pratice. Clin Pharmacol Ther 2008; 84: 287-294.